Granules India Limited Q2 FY26 Concall Decoded: – 34% revenue growth, FDA drama nearing finale, peptides burning cash (for now)

1. Opening Hook

Just when the Street had almost written the script as “another pharma turnaround story stuck in FDA purgatory”, Granules decided to change the plot.
Q2 came in swinging—revenue up 34%, gross margins flexing, and management sounding unusually calm for a company still under a warning letter.

The FDA hasn’t forgiven yet, but it has stopped scolding.
Germany, Denmark, and Switzerland, meanwhile, seem oddly impressed.

And then there’s peptides—bleeding ₹20 crore EBITDA, but spoken of like a future unicorn in a lab coat.

This concall felt less like damage control and more like a trailer for a comeback season.
Stick around—because the real story is less about this quarter and more about what finally unlocks next.

2. At a Glance

Revenue up 34% – Turns out pausing a plant last year helps optics this year.
Gross margin at 65.7% – APIs behaving, formulations smiling.
EBITDA margin at 21.5% – Despite peptides trying their best to ruin the party.
Ascelis EBITDA loss ₹20 Cr – Startup phase, management says “trust us.”
ROCE at 16.2% – Respectable, not brag-worthy.
Net debt ₹1,024 Cr – Capex doesn’t fund itself.

3. Management’s Key Commentary

“We are in the final stages of FDA remediation at Gagillapur.”
(Translation: Please stop asking if the warning letter will last forever.) 😏

“FDA meeting scheduled for January 2026.”
(Translation: The exam date is fixed; results still TBD.)

“No concerns raised by FDA on adequacy or pace of remediation.”
(Translation: Silence is approval… pharma-style.)

“Genome Valley approval unlocks 10 billion additional doses.”
(Translation: Capacity problem solved, demand next.)

“Ascelis Peptides to turn profitable in Q4.”
(Translation: Losses have an expiry date—allegedly.) 🧪

“Swiss innovation, Indian scale resonates strongly.”
(Translation: Europe designs, India manufactures, Wall Street dreams.)

4. Numbers Decoded

Source table

Metric	Q2 FY26	What It Really Says
Revenue	₹1,297 Cr	Base effect + real recovery
Gross Margin	65.7%	Product mix behaving nicely
EBITDA	₹278 Cr	Could’ve been higher without peptides
EBITDA Margin	21.5%	Ops efficiency kicking in
R&D Spend	5.4% of sales	Long-term pain accepted
ROCE	16.2%	Waiting for FDA to juice this

Decoded:
Core pharma is back on track. Optional bets (peptides) are dragging today, promising tomorrow.

5. Analyst Questions (Decoded)

Is growth real or one-off?
Mostly real. Last year’s shutdown helped

To Read Full 16 Point